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Failures in the Detection of HIV p24 Antigen With the Determine HIV-1/2 Ag/Ab Combo Rapid Test TO THE EDITOR-We read with interest the report by Rosenberg et al [1] , showing that the Determine HIV-1/2 Ag/Ab Combo rapid test (Combo RT), in a field evaluation using whole blood collected from at-risk persons, performed poorly in the detection of acute human immunodeficiency virus (HIV) infection. The authors mentioned 2 possible explanations for this low sensitivity: the time course of individuals included in the study and failures in the detection of p24 antigen (Ag), owing either to p24 Ag/antibody (Ab) bound forms, which are unsuitable for detecting p24 Ag in a rapid-test strip, or to a reduced ability to detect clade non-B strains.
We conducted an evaluation study of the Combo RT in 119 dilutions of 66 cell-derived supernatant samples of various HIV-1 and HIV-2 subtypes and in 20 archived plasma samples from individuals with acute-phase HIV-1 infection (Table 1) . Supernatant dilutions were prepared to obtain 3 p24 Ag concentration levels (100, 200, and 400 pg/ mL) and were then tested with a p24 Ag-specific assay (Innotest HIV Antigen mAB assay; Innogenetics) (threshold, 10 ng/mL p24 Ag) to determine the real p24 Ag concentrations. When the upper concentration of a supernatant gave a negative result, a specimen with the highest p24 Ag level (>1000 pg/mL) was tested when available. In addition, the limit of detection of the Combo RT was estimated using 2 reference standards: (1) the World Health Organization Ag standard (HIV-1 isolate, code NIBSC 90/636), prepared in 5 serial dilutions (2-5 IU/mL), and (2) the French national reference p24 Ag panel (SFTS 2007), including 5 dilutions ranging from 25 to 100 pg/mL. All dilutions were prepared in human negative plasma.
The test's limit of detection was established after 6 independent readings, between 2.5 and 3 IU/mL with the World Health Organization standard as the reference, and between 40 and 50 pg/mL with the French standard, which is at least 2-fold higher than the limit of detection reported in the package insert (12.5-25 pg/mL). The overall sensitivity in supernatant samples was 21%, ranging from 0% for 6 HIV-1 group M subtypes (F, G, H, J, CRF06_cpx, and CRF11_cpx), for all HIV-1 groups O (n = 6) and P (n = 1), and HIV-2 [2] . Yet, though not perfect, studies based on artificial samples mimicking primary infections can be assumed to use relevant methods that lead to accurate investigation of assay performance, particularly in non-B infections; HIV Ag/Ab complexes that have a potential negative impact on the capacity of p24 Ag detection do not occur in this situation. As already reported [3] , we have shown that the Combo RT performs poorly in diagnosing HIV acute-phase infections, especially in non-B HIV-1 isolates, irrespective of p24 Ag level. As expected, and in accordance with the manufacturer's indications, HIV-2 Ag was not detected by the assay. In contrast, its ability to detect antibodies (not evaluated here) seems to be equivalent to that of some third-generation antibody assays [1, 4] . Even though we cannot require for rapid tests a sensitivity level as high as those of HIV Ag/Ab combination laboratory assays [5, 6] , owing to the lack of sensitivity of rapid tests in primary infections, we recommend careful evaluation of the results obtained with the Combo RT in pointof-care settings or in blood banks for blood screening, especially in countries with a high prevalence of acute non-B HIV infections.
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